Short radiation with chemo and new drug for rectal cancer
Part of Cancer clinical trials.
This trial tests a short course of radiation followed by chemotherapy and a new drug called ivonescimab, which helps your immune system fight cancer. It is for people with locally advanced rectal cancer that has high-risk features but hasn't spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are generally active and able to care for yourself.
- You have rectal or colorectal cancer that has not spread to distant organs.
- Your tumor is within about 4 inches from the anus.
- Your MRI shows high-risk features like deep tumor growth or lymph node involvement.
- You have not had immunotherapy or pelvic radiation before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This trial tests a new approach for locally advanced rectal cancer. You'll receive a short course of radiation, then chemotherapy plus an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination shrinks the tumor enough to avoid surgery or improve outcomes.
This trial tests a new combination of short-course radiation, an immunotherapy drug called ivonescimab, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard short-course radiation and chemotherapy improves outcomes in people with a common type of locally advanced rectal cancer (pMMR/MSS). It is for those with stage II or III cancer that has at least one high-risk feature and is within 12 cm of the anal verge.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to treat mid- to low rectal cancer. The goal is to potentially improve outcomes while reducing side effects.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.